Free Trial

Steeper After Markets Get A Shot In The Arm

AUSSIE BONDS

The curve runs steeper vs. settlement in early Tuesday trade, with a focus on the positive news surrounding the Moderna vaccine trial, which seemingly bettered last week's offering from Pfizer (there was plenty of talk surrounding this in Asia-Pac trade on Monday). YM -1.0, XM -5.0, with the latter operating a little above its SYCOM low.

  • Bills unchanged to -2 through the reds.
  • Elsewhere, Monday's dinner address from RBA Governor Lowe focused on matters already covered by the RBA i.e. the need to support the labour market and relative monetary policy matters.
  • Today will see further RBA rhetoric from Assistant Governor Kent (currently speaking about the reform of the LIBOR system) & RBA Deputy Governor Debelle (who will speak on the evolution of FX benchmarks). Elsewhere, we will get the release of the minutes from the RBA's most recent monetary policy decision and the pricing of the syndicated tap of ACGB 2.75% 21 May 2041 (for up to A$6.0bn). There will also be some attention placed on the release of the NSW budget.
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.